Merck Profits Soar As MMR Measles Vaccine Increases 27% to $496 Million in 2019
There is nothing like a good "measles outbreak" to boost sales when you have a monopoly on the only measles vaccine available, and corporate-funded mainstream media does almost all of your marketing for free, by singing the praises of the vaccine while never mentioning potential side effects or criminal cases currently in place over corruption surrounding the development of the vaccine. Given the fact that U.S. law prevents anyone from suing Merck if a vaccine injury or death occurs from their vaccines, and that the U.S. Government via the CDC is the largest purchaser of vaccines to the tune of $5 billion per year, the vaccine industry has become perhaps the most lucrative market in the history of the world. Merck & Co Inc. reported higher-than-expected first-quarter profits for 2019. Sales of the MMR measles vaccine soared to 27% to $496 million. The company also saw strong sales growth overseas for its Gardasil vaccine, as sales rose 27 percent to $828 million, beating analyst expectations by about $25 million.











